Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Targeting High Fatality Cancers - Innovation Grant

University of Toronto

$100,000.00

Identification of GBM genetic wiring vulnerabilities.

FY 2015-16

Summary
Glioblastoma is the most common and most aggressive primary brain tumour. The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years. In this proposal we will leverage our ability to interrogate the human genome and identify genes that are essential for the growth of Glioblastoma stem cells, the cells fuelling tumour growth and tutor recurrence after chemotherapy. This work will provide new strategies to treat patients afflicted with this high fatality cancer.
Program
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
341710
Name
Angers Stephane
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Targeting High Fatality Cancers Innovation Grant
Projecttitle
Identification of GBM genetic wiring vulnerabilities.
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Keyworddelim
Crispr; Fitness Gene; Glioblastoma; Wnt
Abstract
Glioblastoma is the most common and most aggressive primary brain tumour. The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years. In this proposal we will leverage our ability to interrogate the human genome and identify genes that are essential for the growth of Glioblastoma stem cells, the cells fuelling tumour growth and tutor recurrence after chemotherapy. This work will provide new strategies to treat patients afflicted with this high fatality cancer.
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Angers, Stephane
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $100,000~ $0~